Shares of Insulet Co. (NASDAQ:PODD - Get Free Report) traded down 4.3% on Tuesday . The company traded as low as $250.14 and last traded at $248.35. 182,281 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 712,180 shares. The stock had previously closed at $259.52.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on PODD shares. Piper Sandler boosted their price target on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus increased their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Citigroup lifted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Royal Bank of Canada started coverage on Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective for the company. Finally, StockNews.com downgraded Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average target price of $292.06.
Check Out Our Latest Research Report on PODD
Insulet Trading Down 3.7 %
The stock has a market cap of $17.54 billion, a P/E ratio of 43.15, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The stock's 50-day moving average is $259.72 and its two-hundred day moving average is $262.09. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.
Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Equities research analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.
Insiders Place Their Bets
In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.47% of the company's stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. purchased a new position in shares of Insulet in the 4th quarter worth approximately $36,000. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet during the fourth quarter valued at approximately $42,000. SRS Capital Advisors Inc. grew its stake in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in shares of Insulet by 553.1% in the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 177 shares during the period. Finally, Friedenthal Financial bought a new stake in shares of Insulet during the 4th quarter worth approximately $57,000.
About Insulet
(
Get Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
